The News

Biolipox appoints Chief Medical Officer

29/08/2006

Biolipox, a Swedish research-intense pharmaceutical company that develops new treatments for inflammatory diseases, has appointed Dr Göran Tornling as new Chief Medical Officer. Prior to joining Biolipox, Dr Tornling held a position as Medical Science Director at AstraZeneca R&D Lund, Sweden. He will join the Executive Management of Biolipox.

”We are very pleased that Göran Tornling has accepted this important role”, says Torbjörn Bjerke. ”Biolipox’s R&D activities are focused on respiratory and inflammatory diseases, and Dr Tornling’s thorough knowledge of the field of Pulmonary Medicine further strengthens the company’s leading competence in the area. In our aim to become a long-term, successful and profitable pharmaceutical company, the projects are conducted with a distinct market focus from the very beginning. Dr Tornling’s prior experience of successfully taking products from preclinical phase to global launch will be a major asset for our development processes.”

Göran Tornling holds a board certificate in Respiratory and Occupational Medicine and is an Associate Professor of Pulmonary Medicine at the Karolinska Institute. He has published more than 70 original scientific articles and will maintain a part-time position at the Karolinska Institute.

”I am very impressed by the creativity and determination that is visible in Biolipox’s drug development programs”, says Göran Tornling. ”All of the projects involve widespread diseases for which there is currently insufficient treatment. Based on its research, Biolipox has created several drug development projects that are based on entirely new treatment principles. I am looking forward to contributing to the company strategies to optimize the processes for development of drugs that meet medical needs.”

For further information please contact:
Torbjörn Bjerke, CEO, Biolipox AB (publ)
Mobile: +46 708 66 19 90 or e-mail
torbjorn.bjerke@biolipox.com

About Biolipox
Biolipox is a research-intense pharmaceutical company. The core of Biolipox's operations is world-leading research on arachidonic acid and its effects on inflammatory diseases - particularly asthma, chronic obstructive pulmonary disease (COPD), rhinitis, pain and arthritis. Through the in-house knowledge in the inflammatory research area, particularly arachidonic acid metabolism, Biolipox has created a portfolio of potential blockbusters in these therapeutic areas. The company has 46 employees and is owned by HealthCap, Apax Partners, Sofinnova Partners, SLS Ventures, Crédit Agricole Private Equity, Auriga Partners and the founders.